María Natalia Gandur Quiroga: Major updates from EAU24 on prostate cancer screening and diagnosis trials
María Natalia Gandur Quiroga shared on X/Twitter:
“Major updates from EAU24 on prostate cancer (PCa) screening and diagnosis trials!
- PRIME study shows biparametric MRI equals multiparametric MRI in detecting significant PCa, suggesting a new standard of care that’s accessible and cost-effective.
- PROBASE Trial challenges current guidelines, suggesting starting risk-adapted screening at age 45 could significantly reduce PCa risk without immediate follow-up for PSA<1.5 ng/ml.
- ProScreen Trial finds combining PSA, kallikrein panel, and MRI improves detection of high-grade PCa, indicating a better balance of benefits and harms compared to PSA screening alone.
These findings could revolutionize PCa screening, making it more effective and accessible!
For full insights, visit the EAU24 Resource Centre.”
Source: María Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.